Baker Bros. Advisors LP Prelude Therapeutics Inc Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,123,824 shares of PRLD stock, worth $14.1 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
10,123,824
Previous 10,123,824
-0.0%
Holding current value
$14.1 Million
Previous $7.8 Million
5.2%
% of portfolio
0.08%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding PRLD
# of Institutions
49Shares Held
27.8MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$15.2 Million0.32% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA933KShares$1.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD928KShares$1.29 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny582KShares$808,7020.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $50.6M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...